Skip to main content
Fig. 2 | Cancer & Metabolism

Fig. 2

From: Normalization of hepatic ChREBP activity does not protect against liver disease progression in a mouse model for Glycogen Storage Disease type Ia

Fig. 2

Prolonged hepatic ChREBP normalization in L-G6pc−/− mice progressively induces hepatomegaly and sensitizes to hepatic inflammation. (A) Liver weight and plasma ALT levels in shChREBP/L-G6pc−/− mice (n = 8). (B) Representative macroscopic liver photos and photos of H&E stainings of livers, and (C) Percent relative cumulative frequency (PRCF) of hepatocyte size. (D) Hepatic glycogen, triglyceride, and protein content (n = 8), (E) hepatic water content, (F) number of inflammatory foci and inflammatory gene expression, and (G) fibrosis marker gene expression in livers of shChREBP/L-G6pc−/− mice (n = 6–9). A, D-G: median ± interquartile range. C: box-and-whisker plots. A-G: Kruskal Wallis H-test, post-hoc Conover pairwise comparisons, *p < 0.05, **p < 0.01, ***p < 0.001 vs shSCR/L-G6pc+/+; ^ vs shChREBP/L-G6pc+/+; # vs shSCR/L-G6pc−/−

Back to article page